2,500-3,000 response units (RUs) of biotinylated HDL were bound to the surface. This was achieved by a 10 µl injection of biotinylated HDL 2 or HDL 3 (1.0 mg protein/ml) at a fl ow rate of 2 µl/min at room temperature. After 5 min, the chip was washed with degassed TBS to remove unattached HDL. A 50 µg/ml human apoE3 solution was fl owed over the chip at 20 µl/min for 2 min to block any remaining hydrophobic surface areas and reduce apoA-I binding to nonHDL sites; the chip was then washed with TBS until the SPR signal reached a steady background value. The surface of the immobilized HDL was then exposed to a 4 min injection of apoA-I dissolved in degassed TBS at a fl ow rate of 20 µl/min to monitor association, and then TBS alone was passed over the sensor surface to monitor apoA-I dissociation from the immobilized HDL particles. For these experiments, two fl ow cells were monitored simultaneously with fl ow cells 1 and 2 containing immobilized biotinylated HDL 2 and HDL 3 , respectively. A sensor chip lacking immobilized HDL could not be used as a reference cell because apoA-I bound more to this surface than to an HDLcoated chip. The apolipoproteins were dialyzed from 6 M guanidine HCl into TBS, fi ltered (Ultrafree, MC centrifugal fi lter devices, 0.1 µm fi lter unit; Millipore, Bedford, MA) and degassed before serial dilutions (20 to 400 µg/ml) were made just prior to injection. The sensor chip was washed two times with 20 µl TBS between each injection of apolipoprotein. The chips were used for 2 days in repetitive experiments. Regeneration of the sensor chip surface was not possible since the lipoproteins were directly immobilized via biotin-streptavidin interaction. The apoA-I sensorgrams were independent of fl ow rate in the range 10-40 l/ min, indicating that the apoA-I binding at 20 l/min was not limited by mass transport (diffusion) effects. Steady state binding isotherms and K d values of the binding to HDL were obtained by generating sensorgrams at different apoA-I concentrations. The sensorgrams were analyzed with the BIA evaluation software version 4.1 (Biacore). The response curves of various apolipoprotein (analyte) concentrations were fi tted to the two-state binding model described by the following equation ( 34, 35 ) . The equilibrium constants of each binding steps are K 1 = ka1 / kd1 and K 2 = ka2 / kd2 , and the overall equilibrium binding constant is calculated as K a = K 1 (1 + K 2 ) and K d = 1 /K a. In this model, the analyte (A) binds to the ligand (HDL) (B) to form an initial complex (AB) and then undergoes subsequent binding or conformational change to form a more stable complex (AB x ). A further check of the two-state binding mechanism was obtained by variation of the contact time for association between the apoA-I and the HDL. For a two-state reaction, an increase in the contact time between the analyte and the ligand decreases the dissociation rate since more of the stable AB x complex is formed. For the apolipoproteins, binding responses in the steady-state region of the sensorgrams (R eq ) were also plotted against apolipoprotein concentration (C) to determine the overall equilibrium binding affi nity. The data were subjected to nonlinear regression fi tting (Prism 4; GraphPad) according to the following equation:
R max is the maximum binding response, and K d is the dissociation constant. We have validated this SPR approach for measuring K d by monitoring the binding of apoE4 to VLDL by SPR as well as ultracentrifugation ( 36 ) and obtained the same K d (data not shown).
Gel fi ltration chromatography
The distribution between the free and bound states of tracelabeled 14 C-apoA-I incubated with HDL 2 was determined using as the application of SPR to the HDL system is concerned, the binding of several plasma remodeling factors to HDL immobilized on a sensor chip has been investigated successfully (24) (25) (26) . Also, the conformation of apoA-I in HDL was explored by comparing the binding of HDL particles to anti-apoA-I monoclonal antibodies immobilized on an SPR chip ( 27 ) . We have extended these approaches to study the binding of apoA-I to HDL particles. The results show that apoA-I can bind reversibly and with low affi nity to HDL particles by a two-step mechanism.
EXPERIMENTAL PROCEDURES

Materials
HDL 2 and HDL 3 were purifi ed by sequential density ultracentrifugation ( 28, 29 ) from a pool of fresh human plasma obtained by combining several single units. Human apoA-I was isolated from the total HDL fraction (1.063 < d < 1.21g/ml) of human plasma as described previously ( 30 ) . Human apoA-I and engineered variants were expressed in Escherichia coli and isolated as reported earlier ( 9, 31 ) . Murine apoA-I and engineered variants were prepared similarly as described before ( 32 ) . Human apoE3 was obtained as formerly reported ( 31 ) .
Biotinylation of HDL particles
HDL 2 and HDL 3 were dialyzed into PBS (pH 7.4) prior to biotinylation. The EZ-link sulfo-NHS-LC-biotinylation kit from Pierce Chemical (Rockford, IL) was used for attaching biotin molecules through a 2.24 nm spacer arm to lysine residues on the surface of HDL particles. HDL 2 and HDL 3 , each at 1.0 mg protein/ml, were mixed with a freshly made 10 mM sulfo-NHS-LCbiotin solution at a 10-fold molar exess of biotin. The lipoproteins were incubated under nitrogen at 4°C overnight before dialysis against TBS (pH 7.4) to remove unreacted sulfo-NHS-LC-biotin. The degree of biotinylation of the particles was determined using conditions recommended by Pierce. Briefl y, solutions containing biotinylated lipoproteins were added to a mixture of 2-(4'-hydroxyphenyl) azobenzoic acid (HABA) reagent and immunopure avidin (Pierce Chemical). Because of its higher affi nity for avidin, biotin, from the biotinylated lipoproteins, displaced avidin-bound HABA. Therefore, the absorbance at 500 nm of the HABA-avidin complex was reduced. The change in absorbance was used to calculate the level of biotin incorporated into the lipoprotein particles. This procedure ordinarily yielded one to two biotin molecules per HDL particle. Such a modifi cation did not change the binding properties of the HDL particle surface as assessed by 14 C-apoA-I binding in an HDL 2 /HDL 3 partition assay using control and biotinylated HDL particles (S. Lund-Katz and M. Nickel, unpublished observations).
SPR
Studies of the binding of apolipoproteins (association and dissociation) to HDL were performed with a Biacore 3000 SPR instrument (Uppsala, Sweden) using SA sensor chips (Biacore, Uppsala, Sweden), as described before for the binding of apoE ( 33 ) . This chip is designed to bind biotinylated ligands through a high-affi nity capture process. Prior to immobilization of HDL on the sensor chip, the streptavidin surface was conditioned with three consecutive 1-min injections of 1 M NaCl in 50 mM NaOH (50 µl/min). The biotinylated HDL 2 or HDL 3 was then immobilized onto the surface through the quasicovalent biotin-streptavidin interaction by exposing the surface to the biotinylated lipoprotein solutions in running buffer (50 mM TBS, pH 7.4) until by guest, on October 14, 2017 www.jlr.org
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conversion of a few lysine residues to monomethylysine ( 37 ) . The 14 C-apoA-I (10 µg) in TBS (pH 7.4) was mixed with unlabeled apoA-I to give the desired total apoA-I concentration and added to HDL 2 to give a fi nal volume of 1.0 ml that contained 1 mg of gel fi ltration chromatography to separate the two pools of apoA-I. 14 C-apoA-I (specifi c activity 2-3 µCi/mg) was prepared by reductive methylation using 14 C-formaldehyde as described before ( 37 ) ; the surface activity of apoA-I is unaffected by this Fig. 2 . SPR analysis of binding of human apoA-I to immobilized HDL 3 . A: Sensorgrams obtained when apoA-I solutions at the indicated concentrations were fl owed across the sensor chip and the experimental data were fi tted with the two-state binding model, where A + B ↔ AB ↔ AB x (see Experimental Procedures). B: Binding isotherm. The maximal response (RU max ) was derived by fi tting sensorgrams obtained over a range of apoA-I concentrations (cf. Fig. 2A ) to the two-state binding model. These RU max values are plotted (mean ± SD, n = 3) as a function of apoA-I concentration and fi tted to a one-site binding model. Figure 1 shows the immobilization of biotinylated HDL on a streptavidin-coated sensor chip when an HDL solution is fl owed across the surface. It is apparent that there is rapid binding to give a steady state level. Flowing buffer HDL 2 protein. The mixture was incubated for 1 h at room temperature to allow the apoA-I to bind to the HDL 2 particles and then subjected to gel fi ltration chromatography on a calibrated Superdex 200 column (60 × 1.6 cm) ( 38 ) . The K av values on this column for HDL 2 and apoA-I were 0.21 and 0.49, respectively. The fractions corresponding to the HDL 2 and free apoA-I peaks were pooled, and the distribution of 14 C-apoA-I determined by liquid scintillation counting. The amount of bound apoA-I per mg HDL 2 was plotted as a function of free apoA-I concentration and fi tted to Equation 2 to derive a K d value.
RESULTS
HDL Immobilization on an SPR chip
Fluorescence measurement of the binding of pyrene-apoA-I to lipid emulsions and HDL 3 Site-specifi c pyrene labeling of cysteine-containing apoA-I variants (V53C and F229C) was performed as described ( 39 ) . Small triolein/egg PC emulsion (SEM) particles (average diameter of 35 ± 5 nm) were prepared by sonication and purifi ed by ultracentrifugation as described ( 40 ) . Fluorescence measurements were carried out with a Hitachi F-7000 fl uorescence spectrophotometer at 25°C. In SEM or HDL 3 binding experiments, pyrene emission fl uorescence of apoA-I (25 g/ml in TBS, pH 7.4) was recorded from 360-500 nm using a 342 nm excitation wavelength at increasing concentrations of SEM or HDL 3 (ratios of PL to protein were 0 Ϫ 80 w/w). To reduce the effect of light scattering caused by lipid particles, the sample was excited with vertically polarized light and measured with a horizontal emission polarizer using a 4 × 4 mm cuvette ( 41 ) . Kinetic data for the increase index effects and fi tted using a two-state binding model (see Experimental Procedures). The kinetic data were not fi tted well by a 1:1 Langmuir binding model, as refl ected by the large value of the goodness of fi t parameter ( 2 > 20 compared with <10 for a global fi t using the two-state model). It follows that the binding of apoA-I to HDL particles involves either a sequential two-step process or some conformational change ( 22, 34, 35 ) . Fitting of the sensorgrams in Fig. 2A gives an association constant K a ‫ف‬ 4 × 10 5 solution alone across the chip washes away a small amount of weakly bound HDL, but the remainder is essentially irreversibly bound by the biotin-streptavidin interaction. In multiple experiments, the amounts of HDL 2 and HDL 3 immobilized by this procedure were 2909 ± 729 and 2761 ± 449 RU (mean ± SD), respectively. The immobilization of HDL in this fashion permits evaluation of the binding of apoA-I, which is diffi cult to monitor in solution because of problems in readily separating HDL and unbound apoA-I. Another advantage of the SPR method is that labeling the apoA-I molecules is not required. A potential problem in the SPR experiment is steric restriction of apoA-I binding by the proximity of the sensor chip surface, but, because HDL particles are attached to the surface by a 2.24 nm spacer arm, protein molecules can access the HDL surface. For example, LCAT ( 24 ) and cholesteryl ester transfer protein ( 26 ) have been shown to bind to HDL in similar SPR experiments.
Kinetics of human ApoA-I binding to HDL Figure 2A shows a typical series of sensorgrams for binding of wild-type (WT) apoA-I at different concentrations to HDL 3 . Similar results were obtained with human plasma apoA-I and when HDL 2 was immobilized on the sensor chip (data not shown). The data are corrected for bulk refractive 
correspond to halftimes of dissociation of 17 s and ‫ف‬ 3 min for the AB and AB x pools, respectively. The rate of dissociation of apoA-I from the HDL surface is dependent upon the length of time the apoA-I is in contact with the particle. As shown in Fig. 3B , progressively shortening the injection (contact) time from 240 s to 60 and 30 s enhances apoA-I dissociation. The fraction of apoA-I in the AB pool increases from ‫ف‬ 0.5 to 0.8 as the contact time is decreased to 30 s, and essentially all the apoA-I is removed at the end of the 4 min dissociation phase. The value of k d1 for the AB pool is not affected by the change in contact time, whereas k d2 approximately doubles as the contact time is decreased to 30 s. These results are consistent with the second step in the two-step mechanism of apoA-I binding to HDL involving a conformational change in the bound apoA-I molecules.
Fitting of the family of sensorgrams depicted in Fig , indicating weak binding of apoA-I to HDL 3 particles. Because the fi tting of the sensorgrams obtained at apoA-I concentrations >100 µg/ml is relatively poor, there is some uncertainty associated with this K a value. Some of the reasons for the diffi culty in modeling the apoA-I/HDL interaction include (1) the interaction is low affi nity, (2) the HDL particles are heterogeneous and do not contain a discrete number of binding sites, and (3) the tendency of apoA-I to self-associate at higher concentrations. Consequently, we employed the steady-state method to compare the binding affi nities of various apoA-I molecules to HDL (see below).
The response curve in Fig. 2A for 50 µg/ml apoA-I fl owed across the sensor chip with immobilized HDL 3 is analyzed in more detail in Fig. 3A . Here the deconvoluted curves show the initial binding (AB) and subsequent binding or conformational changes (AB x ). Because of the uncertainties mentioned above about the valences of the HDL particles, it is diffi cult to interpret the kinetics of association in detail. However, inspection of the deconvoluted curves in Fig. 3A reveals that at the end of the 4 min association phase of the experiment, the sizes of the AB and AB x pools of bound apoA-I are approximately equal in size. It is also apparent that in the dissociation phase (after 4 min), apoA-I molecules in the AB pool dissociate more readily than those in the AB x pool. Analyzing many sensor- apparently do not play a signifi cant role in the binding process because increasing the sodium chloride concentration in the apoA-I-containing running buffer from 0.15-0.5 M did not alter the sensorgram (data not shown). Furthermore, the sensorgrams ( Fig. 3A ) and binding isoof 236 ± 27µg apoA-I/ml (8 ± 1 µM, mean ± SEM) for the binding of human apoA-I to HDL 3 . This K d value indicates that the apoA-I/HDL 3 interaction is of low affi nity and is in a similar range to the K d value of 2-3 µM reported recently by Carnemolla et al. ( 46 ) . Electrostatic interactions Fig. 7 . Comparison of the binding of mouse apoA-I and its tertiary structure domains to HDL 2 . The binding isotherms were obtained and analyzed as described in the legend to Fig. 2B . Circles, WT apoA-I; triangles, N-terminal domain (residues 1-186); diamonds, C-terminal domain (residues 187-240). apoA-I C-terminal domain does not bind to HDL ( Fig. 4 ) . The precision in the determinations of the kinetic parameters for the association of WT apoA-I and its N-terminal domain with HDL was insuffi cient to detect signifi cant differences in the k a and k d values for the two proteins.
To further explore the binding of the N-and C-terminal domains of apoA-I to HDL 3 , we monitored the binding of human apoA-I V53C-pyrene and apoA-I F229C-pyrene by fl uorescence spectroscopy, as we have done before in a small unilamellar vesicle (SUV) system ( 39 ) . When these labeled apoA-I molecules bind to a lipid particle, there is an increase in fl uorescence intensity due to movement of the pyrene moiety into a hydrophobic environment ( Fig. 5 ) . It is apparent from the results in Fig. 5A that the kinetics of binding of the apoA-I C-terminal domain (F229C-pyrene) to SEM and HDL 3 are similar, consistent with the binding being lipid-mediated in both cases. In contrast, the kinetics of interaction of the apoA-I N-terminal helix bundle domain (V53C-pyrene) with the SEM and HDL 3 particles are markedly different ( Fig. 5B ) . The binding titration curves depicted in Fig. 6 reveal the same trends. Thus, the C-terminal domain of apoA-I binds similarly to the SEM and HDL 3 and reaches saturation at about the same PL/apoA-I ratio ( Fig. 6A ). This result indicates that interactions between the therm ( Fig. 2B ) are not affected signifi cantly by any selfassociation of the apoA-I because preparing 50 µg/ml running solutions by dilution of 0.08 and 0.8 mg/ml stock solutions [self-association only occurs in the latter case ( 47 )] gave rise to similar sensorgrams (data not shown). Figure 4A compares the isotherms obtained by SPR for WT human apoA-I and its separate N-(residues 1-189) and C-terminal (residues 190-243) domains binding to HDL 2 . The equivalent binding isotherms to HDL 3 are similar (data not shown). The binding of WT apoA-I to HDL 2 was monitored by both SPR and gel fi ltration chromatography to confi rm that the SPR results are reliable. The binding isotherms for WT apoA-I in Fig. 4A and B are consistent in that the K d values are 12 ± 4 and 8 ± 3 M, respectively. The K d and B max values derived from the isotherms obtained by SPR are listed in Table 1 . It is apparent that removal of the C-terminal domain reduces the amount of apoA-I that binds (lower B max ) but increases the binding affi nity (lower K d ). Removal of the C-terminal ␣ -helix [to give apoA-I (1-222)] also reduces B max but does not signifi cantly reduce K d . The isolated Fig. 8 . SPR sensorgrams of binding of WT human apoA-I and its N-terminal tertiary structure domain (residues 1-189) to immobilized HDL 3 . The sensorgram for total binding (solid line) is for 50 g/ml apoA-I fl owed at 20 l/min, and the initial binding (AB) and subsequent binding (AB x ) contributions were obtained by deconvolution, as described in the legend to Fig. 3 . that the resident apolipoproteins occupy about 80% of the HDL 3 particle surface area.
Contributions of tertiary structure domains of human apoA-I to HDL binding
Infl uence of tertiary structure domain properties on apoA-I binding to HDL
We have taken advantage of the differences in the N-and C-terminal domain properties of human and mouse apoA-I ( 32 ) to explore the infl uence of these properties on the binding of apoA-I to HDL. Figure 7 shows the binding isotherms of WT mouse apoA-I to HDL 2 , and the correhydrophobic apoA-I C-terminal ␣ -helix and lipid dominate the binding to both the SEM and HDL 3 particles. However, the binding behavior of the N-terminal domain is quite different in that it exhibits enhanced binding to HDL 3 compared with the SEM ( Fig. 6B ). This effect is most likely due to protein-protein interactions between the apoA-I N-terminal helix bundle domain and apolipoproteins resident in the HDL 3 particle surface. Such protein-protein interactions can occur readily because it can be estimated from the particle lipid/protein composition and size ( 48 ) Fig. 9 . SPR sensorgrams of binding of WT mouse apoA-I and its N-(residues 1-186) and C-terminal (residues 187-240) tertiary structure domains to immobilized HDL 3 . The data were analyzed as described for human apoA-I in the legend to Fig. 8 . 
Because apoA-I adopts a two-domain tertiary structure ( 5, 9 ) , an obvious possibility is that these two domains bind in a sequential fashion to give the observed kinetics. However, the fact that the WT human apoA-I molecule and its isolated N-terminal domain (residues 1-189) exhibit the same reaction kinetics ( Fig. 8 ) indicates that this is not the case. Apparently, either the N-terminal helix bundle domain or the C-terminal domain can initiate binding to the HDL particle surface. In the SUV situation where the particle surface contains only PL molecules, the rapid initial binding step occurs through the C-terminal domain and the second step involves the subsequent slow opening of the N-terminal helix bundle domain ( 5, 9 ). As depicted in Fig. 10 , this series of events may occur when apoA-I binds to an HDL particle, but the situation is more complex in that an apoA-I molecule can also fi rst bind via its helix bundle domain. Regardless of the mode of initial interaction, the second slower step is proposed to involve helix bundle unfolding ( Fig. 10 ) . In support of this, binding of the isolated mouse N-terminal domain (residues 1-186) exhibits a clear second, slow AB x phase, whereas binding of the isolated mouse C-terminal domain (residues 187-240) does not ( Fig. 9 ) .
Affi nity of apoA-I/HDL interaction
The isotherms depicted in Figs. 4 and 7 together with the binding constants listed in Table 1 give insight into how the properties of the apoA-I tertiary structure domains infl uence the apoA-I/HDL interaction. In marked sponding binding constants are listed in Table 1 . It is apparent that the B max value for WT mouse apoA-I is lower than that of WT human apoA-I, but the K d values for the two proteins are not signifi cantly different; the K d value for WT mouse apoA-I binding to HDL 2 is in excellent agreement with a prior report ( 49 ) . As is observed with human apoA-I, deletion of the C-terminal domain of mouse apoA-I to give mouse apoA-I (1-186) increases the binding affi nity (reduces K d ) and also reduces the amount of binding (lower B max ). In contrast to the situation with the isolated C-terminal domain of human apoA-I, which does not bind to HDL 2 ( Fig. 4 ) , the isolated mouse C-terminal domain binds to HDL 2 in a low affi nity, nonsaturable fashion giving rise to a linear binding isotherm in the concentration range studied ( Fig. 7 ) . The SPR experiments did not reveal signifi cant differences in the binding constants for WT mouse apoA-I interacting with HDL 2 and HDL 3 (data not shown), although Reschly et al. ( 49 ) using different methods showed that this protein binds relatively weakly to HDL 3 . Figures 8 and 9 compare the initial binding (AB) and subsequent binding or conformational change (AB x ) components for WT human and mouse apoA-I and their isolated N-and C-terminal domains binding to HDL 3 . In the case of human apoA-I ( Fig. 8 ), the deconvolution analysis shows that the AB and AB x components are similar for the intact protein and for the isolated N-terminal helix-bundle domain. The level of binding of the isolated C-terminal domain of human apoA-I was too low for the deconvolution analysis to be possible. However, in the case of mouse apoA-I, it was possible to compare the behavior of the isolated N-and C-terminal domains. The results in Fig. 9 demonstrate that the N-terminal domain exhibits two-state binding, whereas the C-terminal domain displays essentially one-state binding with only a very minor AB x component being apparent.
DISCUSSION
Relatively little detailed understanding is available about the interaction of apoA-I with preformed spherical HDL particles, despite the importance of this phenomenon in the cycling of apoA-I between lipid-bound and lipid-free states in the plasma compartment ( 10 ) . This SPR study of the realtime apoA-I association with and dissociation from HDL particles provides novel insights into the mechanism of interaction and information about the affi nity of binding.
Kinetics of apoA-I/HDL interaction
The fact that the sensorgrams depicted in Fig. 2A are best fi tted to a two-state model indicates that some sequential binding events occur when apoA-I molecules bind to HDL particles. The time courses of these two processes (AB and AB x ) are shown in Fig. 3A , from which it is apparent that the dissociation of the initial bound form of apoA-I (AB) is more rapid than that of the subsequent bound form (AB x ). The fact that the length of time apoA-I molecules are in contact with the HDL surface affects the rate of dissociation ( Fig. 3B ) provides strong evidence for the Fig. 10 . Model of the two-step binding mechanism of apoA-I to a spherical HDL particle. Initial binding (Step 1) is rapid and readily reversible and can occur through amphipathic ␣ -helices (cylinders) in either the C-terminal domain (upper pathway) or the N-terminal helix bundle domain (lower pathway) of the apoA-I molecule. In the upper pathway, the C-terminal domain of apoA-I (solid cylinders) fi rst interacts with a lipid site on the HDL particle surface, and Step 2 involves the subsequent opening of the helix bundle whereby hydrophobic helix-helix interactions are converted to helix-lipid interactions.
Step 2 is relatively slow and less readily reversible. In the lower pathway, the apoA-I N-terminal helix bundle domain interacts with a protein site on the HDL particle surface. contrast to what is seen with binding to SUV, where high affi nity binding is eliminated ( 44, 50 ) , removal of either the C-terminal domain or C-terminal ␣ -helix does not disrupt the high affi nity binding of human apoA-I to HDL ( Fig. 4 ) . Furthermore, the isolated C-terminal domain of human apoA-I (residues 190-243) cannot bind to HDL ( Fig. 4 ) , but it can bind well to pure lipid particles ( 32, 51 ) . Removal of the C-terminal domain from WT mouse apoA-I also does not eliminate high affi nity binding to HDL ( Fig. 7 ) . However, this result is consistent with what occurs with binding to SUV and is a consequence of the C-terminal domain of mouse apoA-I (residues 187-240) being relatively polar and having weak lipid binding ability ( 32 ) . Unlike its human counterpart, the isolated mouse C-terminal domain can bind to HDL, albeit in a low affi nity fashion ( Fig. 7 ) . The above differences in behavior point to interactions besides direct apoA-I/lipid interactions being involved in binding of apoA-I to HDL. Indeed, the pyrene-apoA-I fl uorescence data in Figs. 5 and 6 demonstrate that the apoA-I helix bundle domain interacts with apolipoproteins resident in the HDL particle surface. Such proteinprotein interactions are responsible for the lower pathway of apoA-I binding depicted in Fig. 10 .
Physiological implications
A question arises as to the implications of the K d value of ‫ف‬ 10 µM for WT human apoA-I/HDL interaction ( Table  1 ) for the distribution of apoA-I between lipid-bound and lipid-free states in plasma. Assuming that a typical concentration of HDL particles in human plasma is about 16 µM, then it follows that ‫ف‬ 40% of any apoA-I molecules interacting with a K d of 10 µM are in the lipid-free state. Only 5-10% of total plasma apoA-I is in the lipid-free state ( 10 ), so it follows that most apoA-I molecules in HDL particles are more strongly bound and have a lower K d value. The K d of ‫ف‬ 10 µM must apply to a smaller pool of weakly associated apoA-I molecules that are perhaps being held in a "reservoir" state and are not essential structural components of the HDL particle. In support of this idea, several approaches have demonstrated that HDL contains two populations of apoA-I. Thus, there is a labile pool that is readily released by chemical denaturants and susceptible to mild trypsin digestion and another more strongly bound pool that is not released by chemical denaturants and is resistant to trypsin digestion ( 19, 52 ) . Thermal denaturation of spherical HDL also demonstrates the existence of two pools of apoA-I; dissociation of one apoA-I subpopulation causes HDL particle fusion, while dissociation of the second is associated with particle rupture ( 53 ) . Studies of disruption of plasma HDL particles by Streptococcal serum opacity factor indicate that most HDL particles contain at least one labile apoA-I molecule that can dissociate readily ( 54 ) . Finally, the existence of a labile apoA-I pool is consistent with the observation that certain discoidal HDL particles can spontaneously rearrange with the release of some apoA-I molecules ( 55 ) . The strongly bound apoA-I molecules in spherical HDL particles are aligned in a "trefoil" arrangement ( 56 ) , while at least some of the weakly
